Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer (NCT04223856)

🧪 Interventions in This Study

• Enfortumab vedotin (DRUG)
• Pembrolizumab (DRUG)
• Cisplatin (DRUG)
• Carboplatin (DRUG)
• Gemcitabine (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (260 Sites)

Showing the first 25 of 260 sites.

• Ironwood Cancer & Research Centers - Chandler — Chandler, Arizona
• Arizona Oncology Associates PD - HOPE — Tucson, Arizona
• Providence St Joseph Medical Center — Burbank, California
• City of Hope National Medical Center — Duarte, California
• University of California Los Angeles Medical Center — Los Angeles, California
• University of California Irvine - Newport — Orange, California
• Rocky Mountain Cancer Centers - Aurora — Aurora, Colorado
• University of Colorado Hospital / University of Colorado — Aurora, Colorado
• Cancer Centers of Colorado - Denver — Denver, Colorado
• Yale Cancer Center — New Haven, Connecticut
• Eastern CT Hematology and Oncology Associates — Norwich, Connecticut
• Lombardi Cancer Center / Georgetown University Medical Center — Washington D.C., District of Columbia
• H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
• Winship Cancer Institute / Emory University School of Medicine — Atlanta, Georgia
• Georgia Cancer Specialists / Northside Hospital Cancer Institute — Marietta, Georgia
• Louisiana State University/ East Jefferson General Hospital — Metairie, Louisiana
• Maine Health Cancer Care — Biddeford, Maine
• Johns Hopkins Medical Center — Baltimore, Maryland
• Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada
• New Mexico Cancer Center — Albuquerque, New Mexico
• New York University (NYU) Cancer Institute — New York, New York
• Mount Sinai Medical Center — New York, New York
• Memorial Sloan Kettering Cancer Center — New York, New York
• Vidant Medical Center — Greenville, North Carolina
• The Cleveland Clinic — Cleveland, Ohio

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Urothelial Cancer

• A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations — Anchorage, Alaska
• A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer — Cleveland, Ohio
• A Genotype-Phenotype Urothelial Cancer Registry — Basking Ridge, New Jersey
• Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies — Bethesda, Maryland
• Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer — Los Angeles, California

Explore by condition: All Urothelial Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.